Skip to main contentAI and Advanced
/
TORNTPHARM · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
TO
NSE · Equity shares · Biotechnology & Drugs-8.00 · -0.16%
Torrent Pharmaceuticals TORNTPHARM
NSE:INR 5,005
BSE:INR 4,965
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for TORNTPHARM
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 5,013
Day rangeINR 4,964.5 — INR 5,044.5
52-week rangeINR 3,480.6 — INR 5,250
Volume2.45 L
Market cap1.89 L
P/E73.81
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)13,979.73
Net Income (INR Cr)2,163.37
Rev Growth (5 Year %)11.8
EPS Growth (5 Year %)11.56
P/E Ratio73.81
EPS65.49
Research path: Interpret Torrent Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
TORNTPHARMTorrent Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 44,311.96 | 14,989.74 | 15,060.58 |
| Accumulated Depreciation Total | -2,548.64 | -2,239.32 | -2,031.58 |
| Cash Equivalents | 675.19 | 231.52 | 399.29 |
| Other Liabilities Total | 872.52 | 515.53 | 454.89 |
| Accrued Expenses | 487.94 | 233.01 | 224.33 |
| Long Term Debt | 11,651.17 | 1,191.75 | 1,603.78 |
| Common Stock Total | 169.23 | 169.23 | 169.23 |
| Other Equity Total | -430.26 | -250.49 | -180.88 |
| Other Current Assets Total | 22.72 | 11.3 | 29.77 |
| Prepaid Expenses | 98.13 | 63.11 | 58.95 |
| Total Assets | 44,311.96 | 14,989.74 | 15,060.58 |
| Current Portof LT Debt/Capital Leases | 269.69 | 614.74 | 715.99 |
| Cash | 442.01 | 341.96 | 435.85 |
| Total Equity | 8,388.43 | 7,590.69 | 6,856.15 |
| Long Term Investments | 112.51 | 44.57 | 33.29 |
| Retained Earnings(Accumulated Deficit) | 8,649.46 | 7,671.95 | 6,867.8 |
| Total Common Shares Outstanding | 33.84 | 33.84 | 33.84 |
| Property/Plant/Equipment Total-Gross | 7,914.66 | 6,062.23 | 5,609.35 |
| Tangible Book Valueper Share Common Eq | -592.85 | 88.3 | 57.18 |
| Goodwill Net | 3,989.62 | 338.88 | 338.03 |
| Total Liabilities | 35,923.53 | 7,399.05 | 8,204.43 |
| Total Debt | 15,025.5 | 3,202.32 | 4,021.94 |
| Short Term Investments | 1,238.01 | 114.49 | 168.86 |
| Cashand Short Term Investments | 2,355.21 | 687.97 | 1,004 |
| Total Receivables Net | 3,696.18 | 2,259.84 | 2,194.8 |
| Notes Payable/Short Term Debt | 2,914.57 | 1,249.97 | 1,637.71 |
| Deferred Income Tax | 5,670.04 | 828.72 | 656.05 |
| Accounts Receivable-Trade Net | 3,055.85 | 1,866.67 | 1,844.59 |
| Property/Plant/Equipment Total-Net | 5,366.02 | 3,822.91 | 3,577.77 |
| Minority Interest | 9,196.4 | Not available | Not available |
| Total Current Liabilities | 8,343.33 | 4,717.19 | 5,425.25 |
| Total Inventory | 3,219.65 | 2,600.35 | 2,323.96 |
| Accounts Payable | 2,357.61 | 1,820.02 | 2,089.32 |
| Other Currentliabilities Total | 2,313.52 | 799.45 | 757.9 |
| Total Long Term Debt | 11,841.24 | 1,337.61 | 1,668.24 |
| Intangibles Net | 24,463.56 | 4,263.25 | 4,582.82 |
| Other Long Term Assets Total | 722.59 | 621.73 | 582.17 |
| Note Receivable-Long Term | 265.77 | 275.83 | 335.02 |
| Total Current Assets | 9,391.89 | 5,622.57 | 5,611.48 |
| Capital Lease Obligations | 190.07 | 145.86 | 64.46 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio3.95
Price to Sale Ratio13.51
Growth
Debt 5Yr CAGR %25.25
Margins
Operating Margin 12m22.7
Operating Margin 5y Avg22.51
Net Profit Margin 12m13.71
Net Profit Margin 5y14.22
Yield
Dividend Yield %0.76
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk24.46
Analyst consensus
ConsensusBuy
Consensus score2.07
Analyst opinions30
Strong Sell count0
Sell count2
Hold count7
Buy count12
Strong Buy count9
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
| Lupin | INR 2,395 | 1.10 L | 19.12 | — |
Shareholding
Ownership
- Promoter
- 60.78%
- FII
- 17.97%
- MF
- 8.27%
- Other
- 12.98%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal StreetMarket news · 20 Jul 2026, 12:38 pm
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 12 June 2026Market news · 12 Jun 2026, 8:22 am
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 12 June 2026 - Torrent Pharmaceuticals, Kotak Mahindra Bank and Grasim Industries shares.
Stocks to watch today: Hindalco, TVS Motor, Eicher Motors, NTPC, among stocks in focus on 25 May 2026Market news · 25 May 2026, 9:34 am
Stocks to watch today: Hindalco, TVS Motor, Eicher Motors, NTPC, Lupin, Aurobindo Pharma, Torrent Pharmaceuticals, Colgate-Palmolive (India), Camlin Fine Sciences, Groww, Tata Capital, among other stocks are in focus today.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy and sell today - 10 March 2026Market news · 10 Mar 2026, 9:40 am
Shares to buy or sell: Chandan Taparia has recommended two stocks to buy today, 10 March 2026, and one stock to sell. Taparia recommends buying Torrent Pharmaceuticals and MCX shares today, while selling Maruti Suzuki stock futures.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 25 February 2026Market news · 25 Feb 2026, 7:26 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Torrent Pharmaceuticals, CCL Products (India), Schaeffler India, Jammu and Kashmir Bank, and Chennai Petroleum Corporation.
Torrent Pharma share price jumps 6% to hit a record high— Is it a stock to buy, sell or hold after Q3 results?Market news · 16 Feb 2026, 10:39 am
Torrent Pharma's share price jumped as much as 6% in the morning trade on Monday, February 16, to hit a record high of ₹ 4,322.80. Torrent Pharmaceuticals shares opened at ₹ 4,154.95 and jumped over 6% to an all-time high.
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.9.0000 per share(180%)Final Dividend
- board MeetingsAudited Results, Dividend & Fund Raising
- annual General MeetingCOM
- dividendRs.29.0000 per share(580%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsTo consider Fund Raising
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for Torrent Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company focuses on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI), women healthcare (WHC), Vitamins Minerals & Nutrients (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynecology, oncology and anti-infective segments. Its brands include Ahaglow, Shelcal, Tedibar, and Unienzyme. Its tedibar brands include Tedibar bathing bar, Tedibar Atogla, Tedibar Spoo and Tedibar B4 Nappi. Its Shelcal includes Shelcal 500, Shelcal Pro Gummies, Kids Gummies, and Shelcal Total. The Company's manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- TORNTPHARM
- BSE Code
- 500420
Questions
Stock FAQ
What is the symbol and ISIN of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has the symbol TORNTPHARM and ISIN - INE685A01028.
What is the current price of Torrent Pharmaceuticals?
Torrent Pharmaceuticals is currently trading at INR 5,005.00.
What are the year high and year low of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a year high of INR 5,250.00 and a year low of INR 3,480.60.
What is the market capitalization of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a market capitalization of INR 1.89 lakh crore.
What is the P/E ratio of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a P/E ratio of 73.81.
What is the dividend yield of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a dividend yield of 0.76%.
How is the financial performance of Torrent Pharmaceuticals based on revenue, net income, and EPS?
Torrent Pharmaceuticals has revenue of INR 13,979.73 crore, net income of INR 2,163.37 crore, and EPS of INR 64.88.
What is the book value of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a book value of NA.
What is the debt-to-equity ratio of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a price-to-book ratio of NA and a price-to-sales ratio of 13.51.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.